Activated Protein C for Severe Sepsis

To the Editor: In this issue of the Journal, Warren et al.1 and Siegel2 offer their views on the approval of drotrecogin alfa (activated), or recombinant human activated protein C, for the treatment of severe sepsis. We concur with Dr. Siegel's comments regarding the extensive testing to ensure the potency and consistency of drotrecogin alfa (activated) used in the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial.3 It is fortunate that the master cell bank used to produce the drug administered in the latter portion of the trial will be sufficient to meet clinical needs for . . .